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I. Materials and methods
All commercial reagents and solvents were used as received. UPLC-MS analyses were performed using a Waters Acquity TM Ultra Performance LC system equipped with Acquity UPLC® BEH 300 C4, 1.7μm, 2.1 x 100 mm column at a flow rate of 0.3 mL/min. The mobile phase consists of 0.1% formic acid (v/v) and 3.0% acetonitrile (v/v) in water (solvent A) and 0.1% formic acid (v/v) in acetonitrile (solvent B). Preparative HPLC separations were performed using a LabAlliance HPLC solvent delivery system equipped with a Rainin UV-1 detector and (A) a Varian Microsorb 100-5, C18 250x21.4mm column (100 Å pore size) at a flow rate of 16.0 mL/min or (B) a Vydac C18 250x10mm column (218TP1010) at a flow rate of 5.0 mL/min. The mobile phase consists of 0.05% TFA (v/v) in water (solvent A) and 0.04% TFA (v/v) in acetonitrile (solvent B). All circular dichroism (CD) spectra were obtained using an Applied PhotophysicsChirascan TM -plus CD spectrometer.
II. Chemical synthesis of wild-type p53TAD-Biotin 14
H-MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQ-SPh 11
(1) Fully protected peptidyl acid Boc-MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPS-OH 9 Automated peptide synthesis was performed on an Applied Biosystems Pioneer continuous flow peptide synthesizer. Peptides were synthesized under standard automated Fmoc conditions. The deblock solution was a mixture of 100/5/5 of DMF/piperidine/DBU. Fmoc protected amino acid (4.0 eq.), HATU (4.0 eq.) and DIEA (8.0 eq.) were used for the coupling steps. The following amino acids from Chem-Impex International were used: Fmoc-Asp(OMpe) TGT resin from EMD Millipore were employed for the synthesis. Upon completion of automated synthesis on a 0.05 mmol scale, the peptide resin was washed into a peptide cleavage vessel with DCM. The resin cleavage was performed by treatment with AcOH/TFE/DCM (1:1:8) for 2 x 10 mL x 45 mins to yield the fully protected peptidyl acid Boc-MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPS-OH 9. The solvent was removed with compressed air. The oily residue was precipitated with diethyl ether and centrifuged to give a white pellet. After the ether was decanted, the solid was dissolved in 10 mL of MeCN/H 2 O (1:1) and was lyophilized to dryness. 205 mg of crude peptide 9 was obtained in 65% yield. 
MFD procedure of peptide 13
The thiol-substituted peptide 13 (0.16 μmol, 1.30 mg, 0.4 mM, 1.0 eq.) was dissolved in 400 μL of buffer (pH = 6.5) containing 3 M Gn⋅HCl, 100 mM NaH 2 PO 4 , 250 mM TCEP and 40 mM glutathione. Then VA-044 (1.6 μmol, 0.52 mg, 4.0 mM, 10 eq.) was added and the mixture was stirred at 37 o C. The reaction was monitored by UPLC-MS. After 2 hours, upon consumption of the starting material, the reaction was quenched by adding 0.6 mL of MeCN/H 2 O/AcOH (20:20:1). Then the mixture was purified directly by HPLC. After HPLC purification with linear gradient 35-55% B in 30 mins (Varian C18 column, 230 nm wavelength) and lyophilization, 0.66 mg of pure product 14 could be obtained in 51% yield. 
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Figure S4. LC-MS traces and ESI-MS of peptide 14. MS (ESI) calculated for
MFD procedure of peptide 17+2O
The thiol-substituted peptide 17+2O (0.21 μmol, 1.69 mg, 0.26 mM, 1.0 eq.) was dissolved in 800 μL of buffer (pH = 6.5) containing 3 M Gn⋅HCl, 100 mM NaH 2 PO 4 , 250 mM TCEP and 40 mM glutathione. Then VA-044 (2.1 μmol, 0.68 mg, 2.6 mM, 10 eq.) was added and the mixture was stirred at 37 o C. The reaction was monitored by UPLC-MS. After 2 hours, upon consumption of the starting material, the reaction was quenched by adding 1. 
Met(O)-reduction of peptide 18+2O
The Met-oxidized peptide 18+2O (0.08 μmol, 0.65 mg, 0.25 mM, 1.0 eq.) was dissolved in 325 μL of 10% AcOH solution. Then N-methylmercaptoacetamide (7.9 μmol, 0.83 mg, 24 mM, 100 eq.) was added and the mixture was stirred under Argon at 37 o C. The reaction was monitored by UPLC-MS. After 48 hours, upon consumption of the starting material, the mixture was purified directly by HPLC. After HPLC purification with linear gradient 35-55% B in 30 mins (Varian C18 column, 230 nm wavelength) and lyophilization, 0.26 mg of pure product 18 could be obtained in 40% yield. mg, 0.022 mmol, 1.1 eq.) and EDCI (3.4 mg, 0.022 mmol, 1.1 eq.) were added. The mixture was stirred at -10 o C for 1 min and then stirred at room temperature for 2.5 h. The solvent was removed under vacuum. Then 2.0 mL of H 2 O/AcOH (20:1) was added and the mixture was sonicated and centrifuged. The supernatant was discarded and the residue was stirred in 2mL of TFA/TIS/H 2 O (95:2.5:2.5) at room temperature for 5 hours (the cleavage step was monitored by LCMS until the Bzl group of Ser(PO(OBzl)OH and Thr(PO(OBzl)OH) was totally removed). Then the mixture was precipitated by adding dropwise to 20ml of cold ether and centrifuged to give a white pellet. After the ether was decanted, the solid was stirred in 10 mL of MeCN/H 2 O/AcOH (20:20:1) for 12 h at room temperature. Then the mixture was directly purified by HPLC with linear gradient 30-50% B in 30 mins (Varian C18 column, 230 nm wavelength). After lyophilization, 28.1 mg of oxidized product 21+O was obtained in 30% yield. Upon completion of automated synthesis on a 0.05 mmol scale, the peptide resin was washed into a peptide cleavage vessel with DCM. The resin cleavage was performed by treatment with AcOH/TFE/DCM (1:1:8) for S15 2 x 10 mL x 60 mins to yield the fully protected peptidyl acid Boc-CMDDLMLS(PO(OBzl)OH)PDDIEQWFT(PO(OBzl)OH)EDPGPDEAPRMPEAA-OH 20. The solvent was removed under vacuum. The oily residue was precipitated with diethyl ether and centrifuged to give a white pellet. After the ether was decanted, the solid was dissolved in 10 mL of MeCN/H 2 O (1:1) and was lyophilized to dryness. 215 mg of crude peptide 20 was obtained in 76% yield.
(2) Coupling of Boc-CMDDLMLS(PO(OBzl)OH)PDDIEQWFT(PO(OBzl)OH)EDPGPDEAPRMPEAA-OH 20 and Biotin hydrazide 8 Biotin hydrazide 8 (4.2 mg, 0.016 mmol, 1.0 eq.) and fully-protected peptide Boc-CMDDLMLS(PO(OBzl)OH)PDDIEQWFT(PO(OBzl)OH)EDPGPDEAPRMPEAA-OH 20 (100 mg, 0.018 mmol, 1.1 eq.) were dissolved in 340 μL of CHCl 3 /TFE (3:1). At -10 o C, HOOBt (2.9 mg, 0.018 mmol, 1.1 eq.) and EDCI (2.8 mg, 0.018 mmol, 1.1 eq.) were added. The mixture was stirred at -10 o C for 1 min and then stirred at room temperature for 2.5 h. The solvent was removed under vacuum. 1.0 mL of H 2 O/AcOH (20:1) was added and the mixture was sonicated and centrifuged. The supernatant was discarded and the residue was stirred in 2mL of TFA/TIS/H 2 O (95:2.5:2.5) at room temperature for 5 hours (the cleavage step was monitored by LCMS until the Bzl group of Ser(PO(OBzl)OH and Thr(PO(OBzl)OH) was totally removed). Then the mixture was precipitated by adding dropwise to 20ml of cold ether and centrifuged to give a white pellet. After the ether was decanted, the solid was stirred in 10 mL of MeCN/H 2 O/AcOH (20:20:1) for 12 h at room temperature. Then the mixture was directly purified by HPLC with linear gradient 27-47% B in 30 mins (Varian C18 column, 230 nm wavelength). After lyophilization, 9.5 mg of product 22 was obtained in 15% yield. 
MFD procedure of peptide 23+O
The thiol-substituted peptide 23+O (0.52 μmol, 4.48 mg, 0.26 mM, 1.0 eq.) was dissolved in 2 mL of buffer (pH = 6.5) containing 3 M Gn⋅HCl, 100 mM NaH 2 PO 4 , 250 mM TCEP and 40 mM glutathione. Then VA-044 (5.2 μmol, 1.68 mg, 2.6 mM, 10 eq.) was added and the mixture was stirred at 37 o C. The reaction was monitored by UPLC-MS. After 6 hours, upon consumption of the starting material, the reaction was quenched by adding 2 mL of MeCN/H 2 O/AcOH (20:20:1). Then the mixture was purified directly by HPLC. After HPLC purification with linear gradient 32-52% B in 30 mins (Varian C18 column, 230 nm wavelength) and lyophilization, 2.52 mg of product 24+O could be obtained in 57% yield.
S17
Figure S12. 
Met(O)-reduction of peptide 24+O
The Met-oxidized peptide 24+O (0.27 μmol, 2.26 mg, 0.25 mM, 1.0 eq.) was dissolved in 1.1 mL of 10% AcOH solution. Then N-methylmercaptoacetamide (27 μmol, 2.84 mg, 25 mM, 100 eq.) was added and the mixture was stirred under Argon at 37 o C. The reaction was monitored by UPLC-MS. However, neither the starting material nor the product could be detected by UPLC-MS. We also tried the NH 4 I/Me 2 S condition to reduce the Met-oxidized peptide 24+O as shown below. The Met-oxidized peptide 24+O (0.10 μmol, 0.92 mg, 1 mM, 1.0 eq.) was dissolved in 0.1 mL of TFA at 0 o C.
Then NH 4 I (2 μmol, 0.29 mg, 20 mM, 20 eq.) and Me 2 S (2 μmol, 0.12 mg, 20 mM, 20 eq.) were added and the mixture was stirred at 0 o C for 30 mins. The reaction was monitored by UPLC-MS. Again; no desired product could be isolated. 
MFD procedure of peptide 23
The thiol-substituted peptide 23 (0.06 μmol, 0.51 mg, 0.28 mM, 1.0 eq.) was dissolved in 215 μL of buffer (pH = 6.5) containing 3 M Gn⋅HCl, 100 mM NaH 2 PO 4 , 250 mM TCEP and 40 mM glutathione. Then VA-044 (0.6 μmol, 0.19 mg, 2.8 mM, 10 eq.) was added and the mixture was stirred at 37 o C under Argon. The reaction was monitored by UPLC-MS. After 4 hours, upon consumption of the starting material, the reaction was quenched by adding 0.6 mL of MeCN/H 2 O/AcOH (20:20:1). Then the mixture was purified directly by HPLC. After HPLC purification with linear gradient 26-46% B in 30 mins (Vydac C18 column , 230 nm wavelength) and lyophilization, 0.33 mg of product 24 could be obtained in 65% yield.
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Figure S15. 
VI. Circular dichroism (CD) spectra of peptide 14, 18 and 24
The CD spectra were acquired in a 0.5 mm quartz cuvette under nitrogen at a flow rate of 1 L/min. Each peptide was dissolved in 5 mM phosphate buffer with a pH of 7.0 (J. Biol. Chem. 1995, 270:25014-25019) . The peptide concentrations for 14, 18 and 24 were 0.4, 0.15 and 0.4 g/L, respectively. CD spectra were obtained at 20 °C with a step of 0.5 nm, 0.5 s per point and a spectral width of 190-260 nm. The spectra are the average of 5 scans with an averaged 5 scan buffer baseline subtracted. Figure S16 . CD spectra of peptide 14, 18 and 24.
